Actinium Pharmaceuticals, Inc. to Host Corporate Update and Virtual...

Iomab-B has completed several physician sponsored clinical trials examining its potential as a bone marrow conditioning regimen for hematopoietic stem cell transplantation in various blood cancers including a phase I/II study in relapsed and/or refractory elderly acute myeloid leukemia patients.

http://www.biospace.com/news_story.aspx?StoryID=313716&full=1